FDA's Bulk Drug Substance Categories 1, 2 and 3 for Compounders

FDA sorts every bulk drug substance nominated for its 503A and 503B lists into one of three interim categories, and the category a substance sits in changes what a compounding pharmacist can lawfully do with it right now. Category 1 carries FDA's stated enforcement discretion, conditions permitting. Category 2 forfeits it. Treating either as permanent surfaces later in a warning letter.

The Three Interim Categories

The categories come from FDA's current interim policy guidance for both the 503A/503B sections, reissued January 2025. Category 1 covers substances nominated with enough information to evaluate, that do not appear on any other list. Category 2 covers substances with enough information but a significant safety risk FDA has found, and FDA publishes a public notice whenever it adds one. Category 3 covers substances nominated without adequate support to evaluate at all.

What FDA Will and Will Not Do

For a Category 1 substance, FDA has said it does not intend to pursue enforcement, provided conditions hold on the date of compounding: the substance remains in Category 1, the manufacturer is registered, a valid certificate of analysis accompanies it, and the product meets the section's other conditions, including cGMP where applicable. For Category 2, FDA says the opposite just as plainly.

FDA has identified significant safety risks in a Category 2 substance and does not intend to extend the Category 1 enforcement discretion to it.

A substance in Category 3, or never nominated, sits outside the policy, forfeits the section's exemptions, and draws ordinary enforcement.

Entering, Leaving, and Never Entering a Category

A substance reaches a category only after a nomination with the chemistry, safety history, and, for 503B, the clinical-need rationale FDA requires; a bare nomination lands in Category 3 instead. A nominator can withdraw, and FDA updates the list if it was the sole nominator, though FDA may keep evaluating anyway. FDA consults the Pharmacy Compounding Advisory Committee (PCAC) on the 503A side; 503B carries no PCAC requirement. A category ends only through rulemaking, not time. Bulk Drug Substance Sourcing and the Section 503A Lists covers how a substance can lawfully support compounding at all.

The categories changed on January 7, 2025. FDA's current guidance ends sorting newly nominated substances into a category; a substance nominated after that date is evaluated for the list without Category 1's enforcement posture. Substances already categorized keep their policy until FDA addresses them by rule. FDA's review of peptide substances, as a class, has moved between categories more than once; Peptide Compounding: Regulatory Status and the Gray Market covers that history without tying any peptide to a category that may already have changed.

A Category Is Not the Final Bulks List

None of the three categories is the bulks list itself. The list is created by final rule, after notice and comment; only a substance named there is durably eligible. Category 1 reflects FDA's preliminary read that a substance shows no safety risk yet, not a decision it belongs on the list; FDA can still move it to Category 2, or decline to add it after years there. For 503B, the same categories sit beside a separate clinical-need standard; The 503B Bulk Drug Substances List and the Clinical Need Standard covers how FDA applies it.

What an Inspector or Warning Letter Sees

An investigator does not treat a category placement as a defense on its own. The question is whether the conditions behind it were true on the date the product was compounded: was it in Category 1 then, and does the facility's record show it. A later move to Category 2, or removal from Category 1 by final rule, does not excuse earlier compounding; the defense turns on status as of that date. A substance never nominated, or nominated after January 7, 2025, gets no interim discretion, however carefully compounded. Category status says nothing about whether the preparation met USP 797/800 standards or carried a supportable beyond-use date; FDA and state boards inspect those separately, as they do supplier proof.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies and outsourcing facilities promptly retain experienced healthcare defense counsel upon receiving an FDA inspection finding, a warning letter, or any government inquiry tied to bulk drug substance categorization. Early counsel can confirm the substance's actual category status on the relevant date, avoid inadvertent admissions, and communicate with FDA on the pharmacy's behalf. Delaying representation can significantly affect the outcome and expose the pharmacy to unnecessary risk.

How Health Law Alliance Can Help

Health Law Alliance has represented 2,500+ clients nationwide. The firm represents compounding pharmacies and 503B outsourcing facilities facing FDA inspection findings and category disputes. If FDA has raised a category question against your pharmacy, contact Health Law Alliance's compounding pharmacy attorneys for a free, confidential consultation before you respond.